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A Restrospective Analysis of the Association of Obesity with Anthracycline and Trastuzumab
Induced Cardiotoxicity in the Treatment of Cancer
Vienna Figliolini, Ranju Gupta, MD, Deborah Sundlof, MD
Lehigh Valley Health Network, Allentown, Pennsylvania

BACKGROUND / INTRODUCTION

OUTCOMES

RESULTS
Graph 1. Comparison of Dose of AC. Vs. Cardiotoxicity and Obesity

• Anthracycline (AC) and Trastuzumab (Tra) have
been shown to cause significant cardiotoxicity
(CT)
• AC induced CT has been cited as high as 26%
when higher cumulative doses were used (6)
• CT is about 3% to 7% with Tra (7)
• CT is defined as patient with documented
diagnoses of heart failure on the chart,
decrease in LVEF either >15% from baseline or
LVEF<50%, or documented acute coronary
syndrome after AC or Tra based chemotherapy
was initiated
• Doses of AC are calculated based on body
surface area (BSA) and for Tra based on body
weight

Graph 2. Comparison of Dose of Tra Vs. Cardiotoxicity and Obesity

– Obese patients receive a higher cumulative dose of
chemotherapy

• Obesity is inconsistently listed as a risk factor
for CT
• We wanted to confirm if there was a link
between obesity and CT from AC and/or Tra

DISCUSSION
• Age range of patients who acquired CT is 27- 79
• In the cohort without CT only 40% were obese but
within the group that developed CT 50% were obese
• Obese patients that developed CT got an average
cumulative dose of 498 mg of AC or an average
cumulative dose of 15,240 mg of Tra compared to the
obese non-CT patients who received an average
cumulative dose of 479 mg of AC or 10,434 mg of Tra
• Within the group of patients who had CT there was a
high percent of patients with hypertension and/or
diabetes

METHODS
• Retrospective analysis of all patients who
have received AC and/or Tra as part of their
chemotherapy treatment between 2008 and
2012
• All of the information was collected from
MOSAIQ, EPIC, and Centricity
• Data collected includes:
– cancer type, chemotherapy type, dose and duration
– Age, gender, height, weight, BMI, BSA
– Creatinine clearance, hemoglobin, albumin, lipids,
blood pressure, glucose level
– Hospital or outpatient evaluations for congestive
heart failure or shortness of breath, such as, echo,
MUGA, BNP, NT-proBNP, troponin, stress testing,
and cardiac catheterization
– Past heart problems

• Out of the 215 people that received AC 10.2% got CT
• Out of 97 people that received Tra 4.1% got CT
• Out of 23 people who received both AC and Tra 8.7% got CT
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